Efficacy and tolerability of risperidone, yokukansan, and fluvoxamine for the treatment of behavioral and psychological symptoms of dementia: a blinded, randomized trial
| Autor: | Yukio Numata, Yoshiro Okubo, Amane Tateno, Tadahiro Sato, Satoshi Nishino, Kenji Takeyoshi, Mika Teranishi, Masatake Kurita |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
medicine.medical_specialty Time Factors Yokukansan Fluvoxamine law.invention Randomized controlled trial Basal Ganglia Diseases Japan law Activities of Daily Living medicine Dementia Humans Pharmacology (medical) Psychiatry Aged Aged 80 and over Psychiatric Status Rating Scales Risperidone Chi-Square Distribution medicine.disease Functional Independence Measure Psychiatry and Mental health Treatment Outcome Tolerability Multivariate Analysis Physical therapy Anxiety Female medicine.symptom Psychology medicine.drug Central Nervous System Agents Drugs Chinese Herbal |
| Zdroj: | Journal of clinical psychopharmacology. 33(5) |
| ISSN: | 1533-712X |
| Popis: | The descriptive term behavioral and psychological symptoms of dementia (BPSD) is used to cover a range of noncognitive disturbances including anxiety, depression, irritability, aggression, agitation, eating disorders, and inappropriate social or sexual behaviors. Behavioral and psychological symptoms of dementia are seen in about 90% of patients with dementia. We aimed to compare the efficacy and tolerability of risperidone, yokukansan, and fluvoxamine used for BPSD in elderly patients with dementia. Ninety inpatients with dementia according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria were investigated in Sato Hospital, Koutokukai. We conducted an 8-week, rater-blinded, randomized trial, administering flexibly dosed risperidone, yokukansan, or fluvoxamine. Primary outcome measures were Neuropsychiatric Inventory in Nursing Home Version total score and its items. Secondary outcome measures were cognitive function measured by Mini-Mental State Examination and daily life function measured by Functional Independence Measure (FIM). Neurological adverse effects were measured by the Drug-Induced Extra-Pyramidal Symptoms Scale. At the end of the study, we analyzed 76 patients (92.7%). Mean Neuropsychiatric Inventory in Nursing Home Version total score decreased in all 3 drug groups, with no significant between-group differences. Mini-Mental State Examination and Functional Independence Measure scores did not change significantly. Drug-Induced Extra-Pyramidal Symptoms Scale scores did not change in the yokukansan and fluvoxamine groups, but increased significantly in the risperidone group. Risperidone, yokukansan, and fluvoxamine were equally effective in the treatment of BPSD in elderly patients. However, yokukansan or fluvoxamine for BPSD showed a more favorable profile in tolerability compared with risperidone. This trial is registered at UMIN Clinical Trials Registry (identifier: UMIN000006146). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|